KR100656795B1 - 인간의 c형 간염 바이러스 감염을 받을 수 있는 키메라동물 모델 - Google Patents
인간의 c형 간염 바이러스 감염을 받을 수 있는 키메라동물 모델 Download PDFInfo
- Publication number
- KR100656795B1 KR100656795B1 KR1020027012249A KR20027012249A KR100656795B1 KR 100656795 B1 KR100656795 B1 KR 100656795B1 KR 1020027012249 A KR1020027012249 A KR 1020027012249A KR 20027012249 A KR20027012249 A KR 20027012249A KR 100656795 B1 KR100656795 B1 KR 100656795B1
- Authority
- KR
- South Korea
- Prior art keywords
- human
- hcv
- mouse
- host
- chimeric
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 248
- 238000010171 animal model Methods 0.000 title abstract description 56
- 208000010710 hepatitis C virus infection Diseases 0.000 title description 2
- 208000015181 infectious disease Diseases 0.000 claims abstract description 122
- 210000004185 liver Anatomy 0.000 claims abstract description 92
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 50
- 244000052769 pathogen Species 0.000 claims abstract description 41
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 24
- 230000009261 transgenic effect Effects 0.000 claims abstract description 24
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 22
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 12
- 210000003494 hepatocyte Anatomy 0.000 claims description 134
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 108
- 210000002966 serum Anatomy 0.000 claims description 104
- 241000699670 Mus sp. Species 0.000 claims description 96
- 238000002054 transplantation Methods 0.000 claims description 55
- 241000700605 Viruses Species 0.000 claims description 48
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 230000010076 replication Effects 0.000 claims description 33
- 238000011830 transgenic mouse model Methods 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 29
- 230000006870 function Effects 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 238000011081 inoculation Methods 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- 102000009027 Albumins Human genes 0.000 claims description 15
- 108010088751 Albumins Proteins 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 14
- 238000012986 modification Methods 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004895 Lipoproteins Human genes 0.000 claims description 10
- 108090001030 Lipoproteins Proteins 0.000 claims description 10
- 210000005229 liver cell Anatomy 0.000 claims description 10
- 210000005228 liver tissue Anatomy 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 230000002458 infectious effect Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 238000009169 immunotherapy Methods 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000009395 genetic defect Effects 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 230000007056 liver toxicity Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 15
- 230000003908 liver function Effects 0.000 claims 3
- 101150102415 Apob gene Proteins 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 101000930477 Mus musculus Albumin Proteins 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 172
- 108700019146 Transgenes Proteins 0.000 abstract description 44
- 230000000840 anti-viral effect Effects 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 66
- 241000700721 Hepatitis B virus Species 0.000 description 53
- 102000008100 Human Serum Albumin Human genes 0.000 description 47
- 108091006905 Human Serum Albumin Proteins 0.000 description 47
- 230000003612 virological effect Effects 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 35
- 238000011161 development Methods 0.000 description 28
- 230000018109 developmental process Effects 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 241000282412 Homo Species 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 230000001717 pathogenic effect Effects 0.000 description 19
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 17
- 230000029812 viral genome replication Effects 0.000 description 17
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 230000028993 immune response Effects 0.000 description 15
- 238000001262 western blot Methods 0.000 description 15
- 201000001320 Atherosclerosis Diseases 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 14
- 230000001684 chronic effect Effects 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 238000010240 RT-PCR analysis Methods 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 13
- 210000005260 human cell Anatomy 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 230000005867 T cell response Effects 0.000 description 10
- 108020000999 Viral RNA Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 229940036107 hepatitis b immunoglobulin Drugs 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000009385 viral infection Effects 0.000 description 10
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 108010027006 Apolipoproteins B Proteins 0.000 description 8
- 102000018616 Apolipoproteins B Human genes 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 208000002672 hepatitis B Diseases 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000002459 sustained effect Effects 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229960005356 urokinase Drugs 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 102000006382 Ribonucleases Human genes 0.000 description 6
- 108010083644 Ribonucleases Proteins 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 238000012809 post-inoculation Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 102000001938 Plasminogen Activators Human genes 0.000 description 5
- 108010001014 Plasminogen Activators Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 229940127126 plasminogen activator Drugs 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000003118 sandwich ELISA Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 229940125575 vaccine candidate Drugs 0.000 description 4
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- 102000006410 Apoproteins Human genes 0.000 description 3
- 108010083590 Apoproteins Proteins 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 3
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 3
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010052014 Liberase Proteins 0.000 description 3
- 241000283923 Marmota monax Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 102000051631 human SERPINA1 Human genes 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000012317 liver biopsy Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 2
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 208000037741 atherosclerosis susceptibility Diseases 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001436672 Bhatia Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001293164 Eutrema japonicum Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010061993 Haemorrhage neonatal Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000006259 LDL-Receptor Related Proteins Human genes 0.000 description 1
- 108010058141 LDL-Receptor Related Proteins Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 101100230981 Mus musculus Hgf gene Proteins 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 101100230982 Rattus norvegicus Hgf gene Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003999 epithelial cell of bile duct Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 102000045903 human LPA Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229940032219 immunotherapy vaccine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005817 liver abnormality Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 230000026492 vascular transport Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
Abstract
Description
Claims (26)
- 인간 C형 간염 바이러스(HCV)로 감염된 키메라 트랜스제닉 마우스 숙주로서,우로키나제형 플라스미노겐 활성제 폴리펩티드를 코딩하는 폴리뉴클레오티드를 포함하는 게놈을 갖으며, 폴리뉴클레오티드는 숙주 마우스 간세포에서 폴리펩티드가 발현되도록 프로모터에 작동가능하게 연결되어 있는 면역결핍, 트랜스제닉 마우스; 및마우스 숙주 간에 이식된 인간 간세포를 포함하는 키메라 간을 포함하며,키메라 마우스 숙주에의 인간 HCV의 접종은 마우스 숙주의 HCV 감염을 초래하며, 숙주는 폴리뉴클레오티드에 대하여 동형접합성인 것을 특징으로 하는 키메라 트랜스제닉 마우스 숙주.
- 제 1 항에 있어서, 인간의 간세포는 키메라 간의 적어도 20 %의 간세포를 구성하는 것을 특징으로 하는 키메라 마우스 숙주.
- 제 1 항에 있어서, 인간의 간세포는 적어도 15 주 동안 기능하는 것을 특징으로 하는 키메라 마우스 숙주.
- 제 1 항에 있어서, 숙주는 간세포 이식 후에 인간의 C형 간염 바이러스로 감염되는 것을 특징으로 하는 키메라 마우스 숙주.
- 제 4 항에 있어서, 감염된 숙주는 적어도 103 바이러스 입자/mL 혈청을 생산하는 것을 특징으로 하는 키메라 마우스 숙주.
- 제 4 항에 있어서, 감염된 숙주는 적어도 15주의 기간 동안 일정하게 검출가능한 HCV 감염을 유지하는 것을 특징으로 하는 키메라 마우스 숙주.
- 삭제
- 제 1 항에 있어서, 프로모터는 마우스 알부민 프로모터인 것을 특징으로 하는 키메라 마우스 숙주.
- 제 1 항에 있어서, B 및 T 림프구의 결핍은 면역글로불린 및 T 세포 리셉터 유전자 재배열에서의 유전적 결함에 의해 초래되는 것을 특징으로 하는 키메라 마우스 숙주.
- 제 1 항에 있어서, 숙주 면역결핍은 scid 돌연변이에 의해 야기되는 것을 특징으로 하는 키메라 마우스 숙주.
- 인간의 간세포를 우로키나제형 플라스미노겐 활성제 폴리펩티드를 코딩하는 폴리뉴클레오티드를 포함하는 게놈을 갖으며, 폴리뉴클레오티드는 숙주 마우스 간세포에서 폴리펩티드가 발현되도록 프로모터에 작동가능하게 연결되어 있는 면역기능저하, 트랜스제닉 마우스 숙주 내로 이식시키는 단계; 및숙주에 인간의 HCV를 접종하는 단계를 포함하는인간의 C형 간염 바이러스(HCV)로 감염된 키메라 트랜스제닉 마우스 숙주를 생산하는 방법에 있어서,인간-마우스 키메라 간을 포함하고, 인간의 HCV 감염을 가지는 키메라 트랜스제닉 마우스 숙주가 생산되며, 숙주는 폴리뉴클레오티드에 대하여 동형접합성인 것을 특징으로 하는, 키메라 트랜스제닉 마우스 숙주를 생산하는 방법.
- 제 11 항의 방법으로 생산된 키메라 트랜스제닉 마우스 숙주.
- 제 1 항 또는 제 11 항의 키메라 트랜스제닉 마우스 숙주에 인간의 HCV를 투여하는 단계; 및숙주에서 인간의 HCV 복제 후에 감염된 숙주로부터 인간의 HCV를 분리하는 단계를 포함하는, 인간의 C형 간염 바이러스(HCV)를 배양하는 방법.
- 제 1 항 또는 제 11 항의 키메라 트랜스제닉 마우스 숙주에 후보 약제를 투여하는 단계; 및HCV 감염에 대한 후보 약제의 효과를 분석하는 단계를 포함하는, 향간성 병원체에 대항한 활성에 대하여 후보 약제를 스크리닝하는 방법에 있어서,비치료 키메라 트랜스제닉 마우스 숙주 또는 후보 약제투여 전의 키메라 트랜스제닉 마우스 숙주에서의 감염성 부하에 비하여, 인간 HCV의 감염성 부하가 감소하는 것이 약제의 항-HCV 활성의 지표가 되는 것을 특징으로 하는, 후보 약제를 스크리닝하는 방법.
- 제 14 항에 있어서, 후보 약제는 인간의 HCV로 감염되기 전에 투여되는 것을 특징으로 하는 방법.
- 제 15 항에 있어서, 후보 약제는 활성 면역요법용 후보 백신인 것을 특징으로 하는 방법.
- 제 14 항에 있어서, 후보 약제는 치료용 예방접종을 위한 후보 백신인 것을 특징으로 하는 방법.
- 제 14 항에 있어서, 후보약제는 면역치료제인 것을 특징으로 하는 방법.
- 제 18 항에 있어서, 면역치료제는 항-HCV 항체 또는 그것의 HCV-결합 단편인 것을 특징으로 하는 방법.
- 제 1 항 또는 제 11 항의 키메라 트랜스제닉 마우스 숙주에 후보 약제를 투여하는 단계; 및혈청 apoB100 지방단백질에 대한 후보 약제의 효과를 분석하는 단계로 이루어지는, 혈지질 감소 획득에 활성이 있는 후보 약제를 스크리닝하는 방법에 있어서;후보 약제 투여전의 apoB 100 수준에 비하여 후보 약제 투여 후에 감소된 apoB 100 수준이 검출되는 것이 후보 약제가 혈지질 감소 활성을 가진다는 것의 지표가 되는 것을 특징으로 하는, 후보 약제를 스크리닝하는 방법.
- 키메라 면역결핍 트랜스제닉 마우스 숙주에 후보 약제를 투여하는 단계로서, 여기서 숙주는 a) 기능하는 동종 B 및 T 림프구가 결핍되고, b) 우로키나제형 플라스미노겐 활성제 폴리펩티드를 코딩하는 게놈 통합 폴리뉴클레오티드를 갖으며, 폴리뉴클레오티드는 숙주 마우스 간세포에서 폴리펩티드가 발현되도록 프로모터에 작동가능하게 연결되어 있으며, 숙주는 폴리뉴클레오티드에 대하여 동형접합성이고, 그리고 c) 숙주의 간에 이식된 인간의 간세포를 가지는 것을 특징으로 하는 단계; 및간 기능 또는 간 조직에 대한 후보 약제의 효과를 분석하는 단계를 포함하는, 약제의 간 독성을 평가하는 방법에 있어서;비치료 키메라 마우스 숙주 또는 후보 약제 투여전의 간 기능 또는 조직학에 비하여, 치료된 숙주에서의 간 기능의 감소 또는 조직병리학에서의 불리한 변형이, 약제가 간세포에 대하여 독성임의 지표가 되는 것을 특징으로 하는, 간 독성을 평가하는 방법.
- 인간 C형 간염 바이러스(HCV) 감염을 받을 수 있는 키메라 트랜스제닉 마우스로서,우로키나제형 플라스미노겐 활성제 폴리펩티드를 코딩하는 폴리뉴클레오티드를 포함하는 게놈을 갖으며, 폴리뉴클레오티드는 마우스 간세포에서 폴리펩티드가 발현되도록 프로모터에 작동가능하게 연결되어 있는 면역결핍 마우스; 및마우스 간에 이식된 인간 간세포를 포함하는 키메라 간을 포함하며,키메라 마우스에의 인간 HCV의 접종은 마우스의 HCV 감염을 초래하며, 마우스는 폴리뉴클레오티드에 대하여 동형접합성인 것을 특징으로 하는 키메라 트랜스제닉 마우스.
- 제 22 항에 있어서, 프로모터는 알부민 프로모터인 것을 특징으로 하는 키메라 트랜스제닉 마우스.
- 제 22 항에 있어서, 사람 간세포는 마우스 간으로 이식되기 전에는 검출가능한 HCV를 함유하지 않는 것을 특징으로 하는 키메라 트랜스제닉 마우스.
- 인간 C형 간염 바이러스(HCV)로 감염된 키메라 트랜스제닉 마우스로서,우로키나제형 플라스미노겐 활성제 폴리펩티드를 코딩하는 폴리뉴클레오티드를 포함하는 게놈을 갖으며, 폴리뉴클레오티드는 마우스 간세포에서 폴리펩티드가 발현되도록 프로모터에 작동가능하게 연결되어 있는 면역결핍 마우스; 및마우스 간에 이식된 인간 간세포를 포함하는 키메라 간을 포함하며,키메라 마우스에의 인간 HCV의 접종은 마우스의 HCV 감염을 초래하여 감염된 마우스는 적어도 104 바이러스 복제수/mL 혈청을 생산하고, 마우스는 폴리뉴클레오티드에 대하여 동형접합성인 것을 특징으로 하는 키메라 트랜스제닉 마우스.
- 제 25 항에 있어서, 감염된 마우스는 적어도 105 바이러스 복제수/mL 혈청을 생산하는 것을 특징으로 하는 키메라 트랜스제닉 마우스.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/528,120 | 2000-03-17 | ||
US09/528,120 US6509514B1 (en) | 2000-03-17 | 2000-03-17 | Chimeric animal model susceptible to human hepatitis C virus infection |
PCT/CA2001/000350 WO2001067854A1 (en) | 2000-03-17 | 2001-03-16 | Chimeric animal model susceptible to human hepatitis c virus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030027883A KR20030027883A (ko) | 2003-04-07 |
KR100656795B1 true KR100656795B1 (ko) | 2006-12-12 |
Family
ID=24104337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027012249A KR100656795B1 (ko) | 2000-03-17 | 2001-03-16 | 인간의 c형 간염 바이러스 감염을 받을 수 있는 키메라동물 모델 |
Country Status (13)
Country | Link |
---|---|
US (6) | US6509514B1 (ko) |
EP (1) | EP1265480B1 (ko) |
JP (2) | JP4059672B2 (ko) |
KR (1) | KR100656795B1 (ko) |
AT (1) | ATE469547T1 (ko) |
AU (2) | AU4216301A (ko) |
CA (1) | CA2402117C (ko) |
DE (1) | DE60142281D1 (ko) |
DK (1) | DK1265480T3 (ko) |
ES (1) | ES2346636T3 (ko) |
IL (2) | IL151621A0 (ko) |
NZ (1) | NZ521119A (ko) |
WO (1) | WO2001067854A1 (ko) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6995299B2 (en) * | 1999-11-02 | 2006-02-07 | University Of Connecticut | Propagation of human hepatocytes in non-human animals |
US6509514B1 (en) * | 2000-03-17 | 2003-01-21 | Kmt Hepatech, Inc. | Chimeric animal model susceptible to human hepatitis C virus infection |
US20040101827A1 (en) * | 2000-10-03 | 2004-05-27 | Michinori Kohara | Methods of infection with hepatitis c virus |
US20030096316A1 (en) * | 2001-11-21 | 2003-05-22 | Ingmar Wester | Use of apolipoprotein B as a single marker for evaluation of the risk or cardiovascular disease |
CN1642981A (zh) * | 2002-03-25 | 2005-07-20 | 独立行政法人科学技术振兴机构 | 识别增殖性人肝细胞的抗体、增殖性人肝细胞和功能性人肝细胞 |
EP1552740A1 (en) * | 2004-01-09 | 2005-07-13 | Institut Pasteur | Chimeric murine model comprising human hepatocytes - use for screening compounds |
JP2008510465A (ja) * | 2004-08-20 | 2008-04-10 | ケイエムティー ヒパテック インコーポレイテッド | キメラヒト肝臓を有するマラリア動物モデル |
CA2577644C (en) * | 2004-08-20 | 2012-11-27 | Daiichi Pure Chemicals Co., Ltd. | Method for predicting the metabolism of drug in human liver and liver function |
US7566812B2 (en) | 2004-08-27 | 2009-07-28 | Tripep Ab | Transgenic mouse models of hepatitis C virus (HCV) and identification of HCV therapeutics |
JPWO2006054755A1 (ja) * | 2004-11-16 | 2008-06-05 | 財団法人 ひろしま産業振興機構 | 医薬候補物質のスクリーニング方法 |
US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
CA2615626A1 (en) * | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
CN101809156A (zh) * | 2007-06-05 | 2010-08-18 | 俄勒冈健康科学大学 | 体内扩增人类肝细胞的方法 |
US9173383B2 (en) * | 2008-02-21 | 2015-11-03 | The University Of North Carolina At Chapel Hill | Recombinant non-human mammalian model for hepatitis infection and immunopathogenesis |
CN101550425B (zh) * | 2008-03-31 | 2011-03-30 | 北京大学 | 一种可调控的肝损伤动物模型的制作方法及其专用载体 |
JP5710097B2 (ja) * | 2008-07-10 | 2015-04-30 | 株式会社バイオマーカーサイエンス | 動脈硬化改善・予防効果の評価方法、物質のスクリーニング方法、並びに、マーカーとしての使用 |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US8968210B2 (en) * | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
CN101748123B (zh) * | 2008-11-27 | 2012-11-07 | 北京大学 | 可调控肝损伤动物模型的制作方法及其专用dna片段 |
WO2010082385A1 (ja) * | 2009-01-16 | 2010-07-22 | 財団法人実験動物中央研究所 | ヒト肝細胞が移植されたマウス |
JP5841322B2 (ja) | 2010-04-22 | 2016-01-13 | オレゴン ヘルス アンド サイエンス ユニバーシティ | フマリルアセト酢酸ヒドロラーゼ(fah)欠損性ブタおよびその使用 |
US10004826B2 (en) | 2010-10-06 | 2018-06-26 | Massachusetts Institute Of Technology | Implantable human liver tissue constructs and uses thereof |
EP3578042A1 (en) | 2011-08-26 | 2019-12-11 | Yecuris Corporation | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof |
JP5950235B2 (ja) | 2011-09-30 | 2016-07-13 | 公立大学法人横浜市立大学 | 肝細胞の分化誘導方法、ヒト化肝臓キメラ非ヒト動物の作製方法 |
JP5883265B2 (ja) | 2011-10-13 | 2016-03-09 | 株式会社フェニックスバイオ | ヒト肝細胞を担持するキメラ非ヒト動物 |
SG11201402112RA (en) * | 2011-12-06 | 2014-09-26 | Massachusetts Inst Technology | Use of humanized mice to determine toxicity |
US20150052625A1 (en) * | 2012-03-27 | 2015-02-19 | Trans Genic Inc. | Humanized mouse |
JP5976380B2 (ja) * | 2012-04-27 | 2016-08-23 | 公益財団法人東京都医学総合研究所 | ウロキナーゼ型プラスミノーゲンアクチベータートランスジェニックマウス |
WO2014011775A1 (en) | 2012-07-10 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Biomaterials for enhanced implant-host integration |
CN103088106A (zh) * | 2013-01-25 | 2013-05-08 | 中国水产科学研究院淡水渔业研究中心 | 用鱼原代肝细胞损伤模型筛选鱼类保肝药物的方法 |
WO2015073222A1 (en) | 2013-11-01 | 2015-05-21 | Oregon Health & Science University | Normalization of the enterohepatic circulation in animals with a chimeric humanized liver |
US10260111B1 (en) | 2014-01-20 | 2019-04-16 | Brett Eric Etchebarne | Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample |
US11338065B2 (en) | 2015-10-08 | 2022-05-24 | Massachusetts Institute Of Technology | In situ expansion of engineered devices for regeneration |
CN106047870B (zh) * | 2016-06-16 | 2019-01-08 | 中国医学科学院医学生物学研究所 | 树鼩mhc-drb1*1101基因序列及其应用 |
KR102466092B1 (ko) | 2016-06-27 | 2022-11-11 | 베일러 칼리지 오브 메디신 | 결손 p450 산화환원효소를 갖는 인간 간 키메라 비인간 동물 및 이를 이용하는 방법 |
AU2018220843B2 (en) | 2017-02-14 | 2023-09-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
EP3687288A4 (en) * | 2017-09-25 | 2021-06-30 | National University of Singapore | CHEMERICAL ANIMAL INCLUDING STABLE TRANSPLANTED BAT CELLS |
KR102362814B1 (ko) | 2020-06-04 | 2022-02-15 | 한국생명공학연구원 | 인간 간세포 이식용 동물모델 및 이를 이용한 항바이러스제 스크리닝 방법 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476996A (en) * | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5994617A (en) * | 1988-09-19 | 1999-11-30 | Hsc Research Development Corporation | Engraftment of immune-deficient mice with human cells |
EP0438053B1 (en) | 1990-01-15 | 1999-06-16 | Yeda Research And Development Company Limited | Durable engraftment and development of human hematopoietic lineages in normal mammals |
US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
US5804160A (en) | 1991-06-04 | 1998-09-08 | Yeda Research And Development Co. Ltd | Animal model for hepatitis virus infection |
US5849987A (en) | 1992-06-02 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5858328A (en) | 1991-06-04 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Animal model for hepatitis virus infection |
US5408038A (en) | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
IL106368A0 (en) | 1992-07-24 | 1993-11-15 | Univ Pennsylvania | Non-native liver generation in an animal with impaired native liver function,by cell implantation |
CA2161798C (en) | 1993-05-17 | 2005-04-05 | Yair Reisner | Animal model for hepatitis virus infection |
US5980886A (en) * | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
US6107027A (en) | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
WO1996039810A1 (en) | 1995-06-07 | 1996-12-19 | Novartis Ag | Human hepatocellular tissue in chimeric immunocompromised animals |
ATE309006T1 (de) * | 1996-03-15 | 2005-11-15 | Chemo Sero Therapeut Res Inst | Sprühvorrichtung zum aufbringen von gewebeklebstoff |
GB9705744D0 (en) | 1997-03-20 | 1997-05-07 | Davies Alison M | Methods for selecting cells and their uses |
US6034297A (en) | 1997-09-26 | 2000-03-07 | Cedars-Sinai Medical Center | In vivo, animal model for expression of hepatitis C virus |
US6579682B1 (en) | 1998-03-10 | 2003-06-17 | The Regents Of University Of California | Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding |
US6864402B1 (en) | 1998-09-18 | 2005-03-08 | Albert Einstein College Of Medicine Of Yeshiva University | Chronic hepatitis virus infection and clonal hepatocellular carcinoma in mouse repopulated livers |
AU6156399A (en) | 1998-09-18 | 2000-04-10 | Albert Einstein College Of Medicine Of Yeshiva University | Upa/rag-2 mouse with mammalian repopulating hepatocytes for infection by hepadnaviruses |
US6249089B1 (en) * | 1998-10-09 | 2001-06-19 | Frederick Bruwer | Intelligent electrical device comprising microchip |
AU6092900A (en) | 1999-07-14 | 2001-02-05 | Board Of Trustees Of The Leland Stanford Junior University | Animals comprising human hepatocellular tissue |
US6525242B1 (en) | 1999-11-02 | 2003-02-25 | The University Of Connecticut | Propagation of human hepatocytes in non-human mammals |
US6509514B1 (en) | 2000-03-17 | 2003-01-21 | Kmt Hepatech, Inc. | Chimeric animal model susceptible to human hepatitis C virus infection |
-
2000
- 2000-03-17 US US09/528,120 patent/US6509514B1/en not_active Expired - Lifetime
-
2001
- 2001-03-16 DE DE60142281T patent/DE60142281D1/de not_active Expired - Lifetime
- 2001-03-16 KR KR1020027012249A patent/KR100656795B1/ko active IP Right Grant
- 2001-03-16 CA CA2402117A patent/CA2402117C/en not_active Expired - Fee Related
- 2001-03-16 NZ NZ521119A patent/NZ521119A/en not_active IP Right Cessation
- 2001-03-16 EP EP01914893A patent/EP1265480B1/en not_active Expired - Lifetime
- 2001-03-16 ES ES01914893T patent/ES2346636T3/es not_active Expired - Lifetime
- 2001-03-16 AT AT01914893T patent/ATE469547T1/de active
- 2001-03-16 DK DK01914893.1T patent/DK1265480T3/da active
- 2001-03-16 IL IL15162101A patent/IL151621A0/xx active IP Right Grant
- 2001-03-16 AU AU4216301A patent/AU4216301A/xx active Pending
- 2001-03-16 WO PCT/CA2001/000350 patent/WO2001067854A1/en active IP Right Grant
- 2001-03-16 JP JP2001566336A patent/JP4059672B2/ja not_active Expired - Fee Related
- 2001-03-16 AU AU2001242163A patent/AU2001242163B2/en not_active Ceased
-
2002
- 2002-09-04 IL IL151621A patent/IL151621A/en not_active IP Right Cessation
- 2002-09-12 US US10/243,087 patent/US7161057B2/en not_active Expired - Lifetime
-
2006
- 2006-09-07 US US11/517,941 patent/US7498479B2/en not_active Expired - Fee Related
-
2007
- 2007-07-24 JP JP2007191518A patent/JP4436389B2/ja not_active Expired - Fee Related
-
2008
- 2008-12-11 US US12/333,002 patent/US7781642B2/en not_active Expired - Fee Related
-
2010
- 2010-07-20 US US12/840,188 patent/US8212106B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 US US13/484,073 patent/US8445745B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL151621A (en) | 2006-06-11 |
US20070107069A1 (en) | 2007-05-10 |
US20120309032A1 (en) | 2012-12-06 |
US7781642B2 (en) | 2010-08-24 |
US6509514B1 (en) | 2003-01-21 |
US7498479B2 (en) | 2009-03-03 |
JP2003526348A (ja) | 2003-09-09 |
ATE469547T1 (de) | 2010-06-15 |
JP4436389B2 (ja) | 2010-03-24 |
CA2402117C (en) | 2012-01-17 |
US8445745B2 (en) | 2013-05-21 |
US20110167507A1 (en) | 2011-07-07 |
US7161057B2 (en) | 2007-01-09 |
US20030115616A1 (en) | 2003-06-19 |
US8212106B2 (en) | 2012-07-03 |
EP1265480B1 (en) | 2010-06-02 |
JP4059672B2 (ja) | 2008-03-12 |
EP1265480A1 (en) | 2002-12-18 |
JP2008022853A (ja) | 2008-02-07 |
AU2001242163B2 (en) | 2005-06-23 |
DK1265480T3 (da) | 2010-09-20 |
IL151621A0 (en) | 2003-04-10 |
ES2346636T3 (es) | 2010-10-19 |
US20090151012A1 (en) | 2009-06-11 |
CA2402117A1 (en) | 2001-09-20 |
AU4216301A (en) | 2001-09-24 |
KR20030027883A (ko) | 2003-04-07 |
NZ521119A (en) | 2004-03-26 |
WO2001067854A1 (en) | 2001-09-20 |
DE60142281D1 (de) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100656795B1 (ko) | 인간의 c형 간염 바이러스 감염을 받을 수 있는 키메라동물 모델 | |
AU2001242163A1 (en) | Chimeric animal model susceptible to human hepatitis C virus infection | |
US11793178B2 (en) | Fumarylacetoacetate hydrolase (FAH)-deficient and immunodeficient rats and uses thereof | |
JP2003512846A (ja) | ヒト以外の動物におけるヒト肝細胞の増殖 | |
JP2004538012A (ja) | ヒト以外の動物におけるヒト肝芽腫細胞の増殖 | |
US6660905B1 (en) | Mice comprising engrafted functional human hepatocytes | |
US9173383B2 (en) | Recombinant non-human mammalian model for hepatitis infection and immunopathogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121130 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131129 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141124 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151201 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171117 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181115 Year of fee payment: 13 |